Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis.

Amand C, Tong S, Kieffer A, Kyaw MH.

BMC Health Serv Res. 2018 Apr 20;18(1):294. doi: 10.1186/s12913-018-3066-1.

2.

Osteopontin plays a pivotal role in increasing severity of respiratory syncytial virus infection.

Sampayo-Escobar V, Green R, Cheung MB, Bedi R, Mohapatra S, Mohapatra SS.

PLoS One. 2018 Apr 20;13(4):e0192709. doi: 10.1371/journal.pone.0192709. eCollection 2018.

3.

Siglec-1 inhibits RSV-induced interferon gamma production by adult T cells in contrast to newborn T cells.

Jans J, Unger WWJ, Vissers M, Ahout IML, Schreurs I, Wickenhagen A, de Groot R, de Jonge MI, Ferwerda G.

Eur J Immunol. 2018 Apr;48(4):621-631. doi: 10.1002/eji.201747161. Epub 2018 Jan 18.

4.

The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV.

Cullen LM, Schmidt MR, Morrison TG.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2814-2823. doi: 10.1080/21645515.2017.1329069. Epub 2017 Jun 12.

5.

Unexpected Infection Spikes in a Model of Respiratory Syncytial Virus Vaccination.

Smith RJ, Hogan AB, Mercer GN.

Vaccines (Basel). 2017 May 18;5(2). pii: E12. doi: 10.3390/vaccines5020012.

6.

Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997-2012.

Pastula ST, Hackett J, Coalson J, Jiang X, Villafana T, Ambrose C, Fryzek J.

Open Forum Infect Dis. 2017 Jan 9;4(1):ofw270. doi: 10.1093/ofid/ofw270. eCollection 2017 Winter.

7.

A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.

Wang D, Phan S, DiStefano DJ, Citron MP, Callahan CL, Indrawati L, Dubey SA, Heidecker GJ, Govindarajan D, Liang X, He B, Espeseth AS.

J Virol. 2017 May 12;91(11). pii: e00066-17. doi: 10.1128/JVI.00066-17. Print 2017 Jun 1.

8.

Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.

Griffiths C, Drews SJ, Marchant DJ.

Clin Microbiol Rev. 2017 Jan;30(1):277-319. Review.

9.
10.

Epidemiology and clinical characteristics of respiratory syncytial virus infections among children and adults in Mexico.

Gamiño-Arroyo AE, Moreno-Espinosa S, Llamosas-Gallardo B, Ortiz-Hernández AA, Guerrero ML, Galindo-Fraga A, Galán-Herrera JF, Prado-Galbarro FJ, Beigel JH, Ruiz-Palacios GM, Noyola DE; Mexico Emerging Infectious Diseases Clinical Research Network (La Red).

Influenza Other Respir Viruses. 2017 Jan;11(1):48-56. doi: 10.1111/irv.12414. Epub 2016 Aug 18.

11.

Restoration of Retarded Influenza Virus-specific Immunoglobulin Class Switch in Aged Mice.

Zhang Y, Wang Y, Zhang M, Liu L, Mbawuike IN.

J Clin Cell Immunol. 2016 Apr;7(2). pii: 403. Epub 2016 Mar 22.

12.

Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein.

Cullen LM, Blanco JC, Morrison TG.

J Transl Med. 2015 Nov 5;13:350. doi: 10.1186/s12967-015-0705-8.

13.

Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom.

Fleming DM, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, Logie J, Matias G, Taylor S.

BMC Infect Dis. 2015 Oct 23;15:443. doi: 10.1186/s12879-015-1218-z.

14.

Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein.

McGinnes Cullen L, Schmidt MR, Kenward SA, Woodland RT, Morrison TG.

J Virol. 2015 Jul;89(13):6835-47. doi: 10.1128/JVI.00384-15. Epub 2015 Apr 22.

15.

The viral transcription group determines the HLA class I cellular immune response against human respiratory syncytial virus.

Johnstone C, Lorente E, Barriga A, Barnea E, Infantes S, Lemonnier FA, David CS, Admon A, López D.

Mol Cell Proteomics. 2015 Apr;14(4):893-904. doi: 10.1074/mcp.M114.045401. Epub 2015 Jan 29.

16.

Respiratory Viral Infections and Subversion of Cellular Antioxidant Defenses.

Komaravelli N, Casola A.

J Pharmacogenomics Pharmacoproteomics. 2014 Sep 30;5(4). pii: 1000141.

17.

Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study.

Volling C, Hassan K, Mazzulli T, Green K, Al-Den A, Hunter P, Mangat R, Ng J, McGeer A.

BMC Infect Dis. 2014 Dec 13;14:665. doi: 10.1186/s12879-014-0665-2.

18.

A monomeric uncleaved respiratory syncytial virus F antigen retains prefusion-specific neutralizing epitopes.

Swanson KA, Balabanis K, Xie Y, Aggarwal Y, Palomo C, Mas V, Metrick C, Yang H, Shaw CA, Melero JA, Dormitzer PR, Carfi A.

J Virol. 2014 Oct;88(20):11802-10. doi: 10.1128/JVI.01225-14. Epub 2014 Jul 30.

19.

Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory.

Schmidt MR, McGinnes-Cullen LW, Kenward SA, Willems KN, Woodland RT, Morrison TG.

J Virol. 2014 Sep 1;88(17):10165-76. doi: 10.1128/JVI.01250-14. Epub 2014 Jun 25.

20.

Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection.

Bird GH, Boyapalle S, Wong T, Opoku-Nsiah K, Bedi R, Crannell WC, Perry AF, Nguyen H, Sampayo V, Devareddy A, Mohapatra S, Mohapatra SS, Walensky LD.

J Clin Invest. 2014 May;124(5):2113-24. doi: 10.1172/JCI71856. Epub 2014 Apr 17.

Supplemental Content

Support Center